These findings suggest that MCPs have the potential to improve metabolic disorders associated with acute alcohol-induced liver injury by activating the AMPK/SREBP-1c/FAS and PPAR-α/Cpt1a signaling pathways. This evidence concerns the gene SREBF1 and Other metabolic disease.